Navitor Pharmaceuticals Appoints Paul Friedman, MD, To Its Board Of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines targeting the activation of mTORC1, today announced that Paul Friedman, MD, former President & Chief Executive Officer of Incyte Corporation, has joined the Navitor Board of Directors as an independent Director.

Help employers find you! Check out all the jobs and post your resume.